PCM
QNCX icon

Penserra Capital Management’s Quince Therapeutics QNCX Stock Holding History

Penserra Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed -$62K – 1510
2021
Q3 		$62K Hold
3
– – ﹤0.01% 982
2021
Q2 		$35K Hold
3
– – ﹤0.01% 1073
2021
Q1 		$24K Hold
3
– – ﹤0.01% 944
2020
Q4 		$18K Buy
+3
New +$26.6K ﹤0.01% 861

Other funds holding QNCX

ECG
EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Penserra Capital Management's QNCX Position: Q4 2021 in Review

Penserra Capital Management sold out of Quince Therapeutics (QNCX) in Q4 2021, closing a stake of 3 shares — an estimated $62K sold.

Penserra Capital Management first reported a position in QNCX in Q4 2020 and held it in 4 quarters. The position peaked at $62K in Q3 2021. 97 funds tracked by Wall St. Rank hold QNCX as of Q4 2021.

  • Penserra Capital Management reported no remaining Quince Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 3 Quince Therapeutics shares in Q4 2021, an estimated $62K.
  • Penserra Capital Management first reported a position in Quince Therapeutics in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Quince Therapeutics position peaked at $62K in Q3 2021.
  • 97 funds tracked by Wall St. Rank held Quince Therapeutics as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.